Y-mAbs Therapeutics Inc
YMAB4.215USD
-0.315-6.95%
Market hours （ET）Quotes delayed by 15 min
190.73MMarket Cap
LossP/E TTM
More Details of Y-mAbs Therapeutics Inc Company
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Company Info
Ticker SymbolYMAB
Company nameY-mAbs Therapeutics Inc
IPO dateSep 21, 2018
CEOMr. Michael Rossi
Number of employees107
Security typeOrdinary Share
Fiscal year-endSep 21
Address202 Carnegie Center
CityPRINCETON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code08540
Phone16468858505
Websitehttps://www.ymabs.com/
Ticker SymbolYMAB
IPO dateSep 21, 2018
CEOMr. Michael Rossi
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas Gad
Mr. Thomas Gad
Vice Chairman of the Board, Founder, Chief Business Officer
Vice Chairman of the Board, Founder, Chief Business Officer
373.17K
+38.12%
Dr. James I. Healy, M.D., Ph.D.
Dr. James I. Healy, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
53.19K
+89.23%
Mr. Johan Wedell-Wedellsborg
Mr. Johan Wedell-Wedellsborg
Independent Director
Independent Director
27.41K
+1076.39%
Mr. David N. Gill, CPA
Mr. David N. Gill, CPA
Independent Director
Independent Director
27.41K
+1076.39%
Dr. Ashutosh Tyagi, M.D.
Dr. Ashutosh Tyagi, M.D.
Independent Director
Independent Director
27.41K
+1076.39%
Dr. Mary Tagliaferri, M.D.
Dr. Mary Tagliaferri, M.D.
Independent Director
Independent Director
1.55K
--
Mr. Peter P. Pfreundschuh, CPA
Mr. Peter P. Pfreundschuh, CPA
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
--
--
Mr. Douglas J Gentilcore
Mr. Douglas J Gentilcore
Senior Vice President, Danyelza Business Unit Head
Senior Vice President, Danyelza Business Unit Head
--
--
Ms. Laura Jean Hamill
Ms. Laura Jean Hamill
Independent Director
Independent Director
--
--
Mr. Joris Wiel Jan Wilms
Mr. Joris Wiel Jan Wilms
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas Gad
Mr. Thomas Gad
Vice Chairman of the Board, Founder, Chief Business Officer
Vice Chairman of the Board, Founder, Chief Business Officer
373.17K
+38.12%
Dr. James I. Healy, M.D., Ph.D.
Dr. James I. Healy, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
53.19K
+89.23%
Mr. Johan Wedell-Wedellsborg
Mr. Johan Wedell-Wedellsborg
Independent Director
Independent Director
27.41K
+1076.39%
Mr. David N. Gill, CPA
Mr. David N. Gill, CPA
Independent Director
Independent Director
27.41K
+1076.39%
Dr. Ashutosh Tyagi, M.D.
Dr. Ashutosh Tyagi, M.D.
Independent Director
Independent Director
27.41K
+1076.39%
Dr. Mary Tagliaferri, M.D.
Dr. Mary Tagliaferri, M.D.
Independent Director
Independent Director
1.55K
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2024Q2
No Data
By RegionUSD
Name
Revenue
Proportion
United States
65.98M
77.46%
Eastern Asia
7.46M
8.75%
Latin America
4.72M
5.54%
Western Asia
4.05M
4.76%
Western Europe
2.09M
2.45%
Other region
890.00K
1.04%
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Jul 27
Updated: Sun, Jul 27
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
WG Biotech ApS
10.07%
Paradigm BioCapital Advisors LP
9.35%
HBM Partners AG
7.28%
Acorn Capital Advisors, LLC
6.10%
BlackRock Institutional Trust Company, N.A.
5.65%
Other
61.55%
Shareholders
Shareholders
Proportion
WG Biotech ApS
10.07%
Paradigm BioCapital Advisors LP
9.35%
HBM Partners AG
7.28%
Acorn Capital Advisors, LLC
6.10%
BlackRock Institutional Trust Company, N.A.
5.65%
Other
61.55%
Shareholder Types
Shareholders
Proportion
Investment Advisor
26.79%
Hedge Fund
20.03%
Investment Advisor/Hedge Fund
15.62%
Corporation
10.07%
Venture Capital
5.05%
Research Firm
2.73%
Individual Investor
2.18%
Bank and Trust
0.21%
Pension Fund
0.16%
Other
17.17%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
264
37.72M
83.28%
-923.46K
2025Q1
277
38.42M
85.49%
-1.59M
2024Q4
273
40.45M
90.45%
-6.61K
2024Q3
291
40.17M
90.02%
+2.08M
2024Q2
285
38.93M
87.51%
+1.55M
2024Q1
287
37.98M
86.27%
+2.28M
2023Q4
288
35.14M
80.00%
-1.12M
2023Q3
292
32.75M
75.02%
-3.59M
2023Q2
292
32.24M
73.87%
-4.59M
2023Q1
293
31.07M
71.14%
-6.37M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
WG Biotech ApS
4.56M
10.07%
--
--
May 23, 2025
Paradigm BioCapital Advisors LP
4.24M
9.35%
--
--
Mar 31, 2025
HBM Partners AG
3.30M
7.28%
--
--
May 23, 2025
Acorn Capital Advisors, LLC
2.76M
6.1%
--
--
May 23, 2025
BlackRock Institutional Trust Company, N.A.
2.56M
5.65%
-129.60K
-4.82%
Mar 31, 2025
Caligan Partners, LP
2.34M
5.17%
+574.63K
+32.50%
Mar 31, 2025
Sofinnova Investments, Inc
2.19M
4.84%
--
--
May 23, 2025
The Vanguard Group, Inc.
1.95M
4.3%
-46.73K
-2.34%
Mar 31, 2025
Polar Capital LLP
1.83M
4.04%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
849.50K
1.88%
+27.19K
+3.31%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ALPS Medical Breakthroughs ETF
0.14%
iShares Micro-Cap ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
View more
ALPS Medical Breakthroughs ETF
Proportion0.14%
iShares Micro-Cap ETF
Proportion0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
